Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Toby Pepperrell
Reshaping trade for vaccine equity: gaps in policy discourse
TP is Visiting Research Fellow at the Global Health Academy University of Edinburgh and conducted this work alongside a Regenerative Economics MA at Schumacher College University of Plymouth. He is a member of Peoples Health Movement (PHM) Scotland and Universities Allied for Essential Medicine (UAEM). He is employed as a research consultant through MetaVirology.
Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine?
Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine?
Who funded the research behind the Oxford-AstraZeneca COVID-19 vaccine? Approximating the funding to the University of Oxford for the research and development of the ChAdOx vaccine technology
Abstract Objectives The Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19 or Vaxzevira) builds on nearly two decades of research and development (R&D) into Chimpanzee adenovirus-vectored vaccine (ChAdOx) technology at the University of Oxford. This study aims to approximate the funding for the R&D of the ChAdOx technology and the Oxford-AstraZeneca vaccine, and assess the transparency of funding reporting mechanisms.
Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs
Abstract Background Several drugs are being repurposed for the treatment of the coronavirus disease 2019 (COVID-19) pandemic based on in vitro or early clinical findings. As these drugs are being used in varied regimens and dosages, it is important to enable synthesis of existing safety data from clinical trials. However, availability of safety information is limited by a lack of timely reporting of overall clinical trial results on public registries or through academic publication.
Missing clinical trial data: the knowledge gap in the safety of potential COVID-19 drugs
Abstract Abstract (290/300 words) Objectives: Several drugs are being repurposed for the treatment of the coronavirus disease 2019 (COVID-19) pandemic based on in vitro or early clinical findings. As these drugs are being used in varied regimens and dosages, it is important to enable synthesis of existing safety data from clinical trials.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Toby
Contact Toby, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack